Home Epigenetics Epigenetic Reader Domain inhibitor Apabetalone (RVX-208) For research use only.

Apabetalone (RVX-208)

Synonyms: RVX-000222

Apabetalone (RVX-208, RVX-000222) is a potent BET bromodomain inhibitor with IC50 of 0.510 μM for BD2 in a cell-free assay, about 170-fold selectivity over BD1. Phase 2.

Apabetalone (RVX-208) Chemical Structure

Apabetalone (RVX-208) Chemical Structure

CAS: 1044870-39-4

Selleck's Apabetalone (RVX-208) has been cited by 18 Publications

3 Customer Reviews

Purity & Quality Control

Batch: Purity: 99.85%
99.85

Apabetalone (RVX-208) Related Products

Signaling Pathway

Epigenetic Reader Domain Signaling Pathways

Epigenetic Reader Domain Signaling Pathway

Choose Selective Epigenetic Reader Domain Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2 Function assay ~60 μM DMSO induces apoA-I mRNA and de novo synthesis of apoA-I. 20513599
U2OS Function assay ~5 μM displaces BET proteins from chromatin 24248379
BL21(DE3)-R3-pRARE2 Function assay Inhibition of recombinant human His6-tagged BRD4 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells preincubated for 30 mins followed by HSGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK(Biotin)-OH peptide substrate addition after 30 mins by alphas, Kd = 0.135 μM. 28195723
BL21(DE3) Function assay Binding affinity to human BRD4 bromodomain 2 expressed in Escherichia coli BL21 (DE3) cells by isothermal titration calorimetry, Kd = 0.14 μM. 26367539
BL21(DE3)-R3-pRARE2 Function assay Inhibition of recombinant human His6-tagged BRD3 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells, Kd = 0.195 μM. 28195723
BL21(DE3) Function assay Binding affinity to human BRD2 bromodomain 2 expressed in Escherichia coli BL21 (DE3) cells by isothermal titration calorimetry, Kd = 0.25 μM. 26367539
BL21(DE3)-R3-pRARE2 Function assay Inhibition of recombinant human His6-tagged BRD2 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells, Kd = 0.251 μM. 28195723
BL21(DE3) Function assay Binding affinity to human BRD4 bromodomain 1 expressed in Escherichia coli BL21 (DE3) cells by isothermal titration calorimetry, Kd = 1.1 μM. 26367539
BL21(DE3)-R3-pRARE2 Function assay Inhibition of recombinant human His6-tagged BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells preincubated for 30 mins followed by H4K5acK8acK12acK16ac peptide substrate addition after 30 mins by alphascreen assay, Kd = 1.142 μM. 28195723
SAE Function assay 24 hrs Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced ISG54 RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis, IC50 = 2.63 μM. 29649741
SAE Function assay 24 hrs Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced ISG56 RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis, IC50 = 2.74 μM. 29649741
SAE Function assay 24 hrs Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced grobeta RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis, IC50 = 3.73 μM. 29649741
SAE Function assay 24 hrs Inhibition of BRD4 in human SAE cells assessed as reduction in TLR3 agonist poly(I:C) -induced IL-8 RNA expression preincubated for 24 hrs followed by poly(I:C) addition and measured after 4 hrs by SYBR green dye-based qRT-PCR analysis, IC50 = 3.85 μM. 29649741
BL21(DE3)-R3-pRARE2 Function assay Inhibition of recombinant human His6-tagged BRD3 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells, Kd = 4.065 μM. 28195723
MV4-11 Antiproliferative assay 72 hrs Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay, IC50 = 4.48 μM. 28765013
BL21(DE3)-R3-pRARE2 Function assay Inhibition of recombinant human His6-tagged BRD2 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells, Kd = 5.78 μM. 28195723
BL21(DE3) Function assay Binding affinity to human BRD2 bromodomain 1 expressed in Escherichia coli BL21 (DE3) cells by isothermal titration calorimetry, Kd = 5.8 μM. 26367539
OCI-AML3 Antiproliferative assay 72 hrs Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay, IC50 = 7.17 μM. 28765013
OCI-AML2 Antiproliferative assay 72 hrs Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay, IC50 = 8.31 μM. 28765013
MCF7 Autophagy assay 150 uM Induction of autophagy in human MCF7 cells assessed as downregulation of p62/SQSTM1 expression at 150 uM by Western blot analysis 29172540
MDA-MB-231 Autophagy assay 150 uM Induction of autophagy in human MDA-MB-231 cells assessed as downregulation of p62/SQSTM1 expression at 150 uM by Western blot analysis 29172540
Click to View More Cell Line Experimental Data

Biological Activity

Description Apabetalone (RVX-208, RVX-000222) is a potent BET bromodomain inhibitor with IC50 of 0.510 μM for BD2 in a cell-free assay, about 170-fold selectivity over BD1. Phase 2.
Features First-in-class BD2-selective inhibitor of BET bromodomain and has been tested in Phase II clinical trials for treatment of coronary syndromes and atherosclerosis.
Targets
BD2 [1]
(Cell-free assay)
0.51 μM
In vitro
In vitro As a BET bromodomain inhibitor, RVX-208 preferentially binds to the second bromodomain found on BET proteins. [1] RVX-208, as a stimulator of apolipoprotein (APO) AI gene expression, increases apoA-I and HDL-C in vitro. [2] [3]
Experimental Result Images Methods Biomarkers Images PMID
Western blot Phospho-RelA / Total-RelA / Actin / BRD2 / α-Tubulin Cyclin T1 / CDK9-55kDa / CDK9-42kDa / p-CDK9 / CTD / CTD-Ser2P / p24 / β-actin Rb / p-Rb(S780) / p-Rb(S795) / p-Rb(S807/811) / β-actin cyclin D1 / CDK4 / CDK6 / p24 / β-actin p21 / p24 / β-actin 31300040
Immunofluorescence DNA SARS-CoV-2 CTNT monocyte adhesion 33811809
In Vivo
In vivo RVX-208 significantly increases serum apoA-I and HDL-C in AGMs, and enhances cholesterol efflux via different pathways. [3]
Animal Research Animal Models Naïve adult male AGMs
Dosages ~60 mg/kg
Administration Oral gavage or intravenous administration
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03160430 Not yet recruiting
Kidney Failure Chronic
Resverlogix Corp
 November 22 2024 Phase 1|Phase 2
NCT03228940 Withdrawn
Fabry Disease
Resverlogix Corp
 November 22 2022 Phase 1|Phase 2
NCT01863225 Terminated
Dyslipidemia|Coronary Artery Disease
Resverlogix Corp|South Australian Health and Medical Research Institute
 May 2013 Phase 2
NCT01728467 Completed
Diabetes
Resverlogix Corp|Baker Heart and Diabetes Institute|Nucleus Network Ltd
 November 2012 Phase 2
NCT01067820 Completed
Coronary Artery Disease
Resverlogix Corp|The Cleveland Clinic
 September 2011 Phase 2
NCT01423188 Completed
Coronary Artery Disease|Dyslipidemia
Resverlogix Corp|The Cleveland Clinic
 August 2011 Phase 2

Chemical Information & Solubility

Molecular Weight 370.4 Formula

C20H22N2O5
CAS No. 1044870-39-4 SDF Download Apabetalone (RVX-208) SDF
Smiles CC1=CC(=CC(=C1OCCO)C)C2=NC3=C(C(=CC(=C3)OC)OC)C(=O)N2
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 74 mg/mL ( (199.78 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Apabetalone (RVX-208) | Apabetalone (RVX-208) supplier | purchase Apabetalone (RVX-208) | Apabetalone (RVX-208) cost | Apabetalone (RVX-208) manufacturer | order Apabetalone (RVX-208) | Apabetalone (RVX-208) distributor